Graham Pawelec
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Graham Pawelec has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Medi Adibzadeh
Tübingen Ageing and Tumour Immunology Group, Section for Transplantation Immunology and Immunohaematology, Second Department of Internal Medicine, University of Tübingen Medical School, Tübingen, Germany
4 shared publicationsArnika Rehbein
Tübingen Ageing and Tumour Immunology Group, Section for Transplantation Immunology and Immunohaematology, Second Department of Internal Medicine, Tübingen University Medical School, Tübingen, Germany DE
3 shared publicationsAndrea Engel
Tübingen Ageing and Tumour Immunology Group, Section for Transplantation Immunology and Immunohaematology, Second Department of Internal Medicine, University of Tübingen Medical School, Tübingen, Germany
2 shared publicationsHubert Kalbacher
Medical and Natural Sciences Research Center, University of Tübingen, Tübingen, Germany DE
2 shared publicationsKarin Hähnel
2 shared publications- Rafael Solana
Department of Cell Biology, Physiology and Immunology, Universidad de Córdoba, Córdoba, Spain
2 shared publications
Latest Publications
- 15 October 1999
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 48 (8) , 430-434
IFN-α regulates IL 10 production by CML cells in vitro
High levels of spontaneous in vitro IL 10 secretion by a subset of untreated chronic phase CML patients' cells are shown to be decreased in the presence of IFN-α. However, the lower level of spontaneous IL 10 secretion by healthy control cells are was not depressed by IFN-α. In contrast to its effects on IL 10 production, IFN-α increased the low spontaneous secretion of IL 1α by patients' cells, bud did not further increase the higher levels of spontaneous IL 1β secretion by normal cells. It had no effect on secretion of TNF-α by patients or normals. Spontaneous secretion of IL-1α (or IFN-γ) by patients' cells was not observed whether or not IFN-α was present. Therefore, one mechanism of action of IFN-α in vivo may involve decreasing endogenous IL 10 secretion (thereby reducing suppressive effects on T cell reactivity) and increasing IL 1β secretion (thereby enhancing antigen presentation).
- 15 October 1999
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 48 (8) , 430-434
IFN-α regulates IL 10 production by CML cells in vitro
High levels of spontaneous in vitro IL 10 secretion by a subset of untreated chronic phase CML patients' cells are shown to be decreased in the presence of IFN-α. However, the lower level of spontaneous IL 10 secretion by healthy control cells are was not depressed by IFN-α. In contrast to its effects on IL 10 production, IFN-α increased the low spontaneous secretion of IL 1α by patients' cells, bud did not further increase the higher levels of spontaneous IL 1β secretion by normal cells. It had no effect on secretion of TNF-α by patients or normals. Spontaneous secretion of IL-1α (or IFN-γ) by patients' cells was not observed whether or not IFN-α was present. Therefore, one mechanism of action of IFN-α in vivo may involve decreasing endogenous IL 10 secretion (thereby reducing suppressive effects on T cell reactivity) and increasing IL 1β secretion (thereby enhancing antigen presentation).
- 13 June 1999
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 48 (4) , 214-217
Prerequisites for the Immunotherapy of Cancer
Tumours express proteins not commonly found in normal cells, or over-express certain proteins. These may in some cases serve as target antigens for immunological attack. It is therefore essential to improve our understanding of the nature of these target epitopes and the cells which recognize them, in order to develop immunotherapy as a realistic treatment for cancer. A small group of around 40 investigators recently came together at the Heinrich Fabri Institute of the University of Tübingen to discuss the identification of human tumour antigens and the exploitation of this knowledge for effective immunotherapy.
- 13 June 1999
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 48 (4) , 214-217
Prerequisites for the Immunotherapy of Cancer
Tumours express proteins not commonly found in normal cells, or over-express certain proteins. These may in some cases serve as target antigens for immunological attack. It is therefore essential to improve our understanding of the nature of these target epitopes and the cells which recognize them, in order to develop immunotherapy as a realistic treatment for cancer. A small group of around 40 investigators recently came together at the Heinrich Fabri Institute of the University of Tübingen to discuss the identification of human tumour antigens and the exploitation of this knowledge for effective immunotherapy.
- 1 June 1999
- Published by Elsevier in Experimental Gerontology
- Vol. 34 (3) , 419-429
T cell immunosenescence in vitro and in vivo
- 1 June 1999
- Published by Elsevier in Experimental Gerontology
- Vol. 34 (3) , 419-429
T cell immunosenescence in vitro and in vivo
- 1 April 1999
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 108 (1) , 1-7
Editorial
- 1 April 1999
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 108 (1) , 1-7
Editorial
- 1 January 1999
- Published by Elsevier in Experimental Gerontology
- Vol. 34 (1) , 69-77
Finite lifespans of t cell clones derived from CD34+ human haematopoietic stem cells in vitro
- 1 January 1999
- Published by Elsevier in Experimental Gerontology
- Vol. 34 (1) , 69-77
Finite lifespans of t cell clones derived from CD34+ human haematopoietic stem cells in vitro
- 1 January 1999
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 4 (1-3) , d216-69
T cells and aging (update February 1999)
Deterioration of the immune system with aging ("immunosenescence") is believed to contribute to morbidity and mortality in man due to the greater incidence of infection, as well as possibly autoimmune phenomena and cancer in the aged. Dysregulation of T cell function is thought to play a critical part in these processes. Factors contributing to T cell immunosenescence may include a) stem cell defects, b) thymus involution, c) defects in antigen presenting cells (APC), d) aging of resting immune cells, e) disrupted activation pathways in immune cells, f) replicative senescence of clonally expanding cells. This review aims to consider the current state of knowledge on the scientific basis for and potential clinical relevance of those factors in immunosenescence.
- 1 January 1999
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 4 (1-3) , d216-69
T cells and aging (update February 1999)
Deterioration of the immune system with aging ("immunosenescence") is believed to contribute to morbidity and mortality in man due to the greater incidence of infection, as well as possibly autoimmune phenomena and cancer in the aged. Dysregulation of T cell function is thought to play a critical part in these processes. Factors contributing to T cell immunosenescence may include a) stem cell defects, b) thymus involution, c) defects in antigen presenting cells (APC), d) aging of resting immune cells, e) disrupted activation pathways in immune cells, f) replicative senescence of clonally expanding cells. This review aims to consider the current state of knowledge on the scientific basis for and potential clinical relevance of those factors in immunosenescence.
- 1 December 1998
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 64 (6) , 703-712
Impact of aging on innate immunity
Immune responses in higher organisms are triggered by the recognition of a limited diversity of microbiological products by cells of the innate or “natural” immune system. As a result, in addition to the direct protective effect of natural immunity, antigen‐presenting cells, particularly dendritic cells, are activated to process and present an enormous number of peptide antigens to the T lymphocytes of the adaptive immune system. These, together with the B lymphocytes, then mediate specific immune responses and maintain acquired immunological memory. The aging immune system is less well able to cope with infectious disease than the youthful immune system; this review will briefly consider what is known of the age‐associated alterations in innate immunity, and how these may also impact on adaptive immunity. J. Leukoc. Biol. 64: 703–712; 1998.
- 1 December 1998
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 64 (6) , 703-712
Impact of aging on innate immunity
Immune responses in higher organisms are triggered by the recognition of a limited diversity of microbiological products by cells of the innate or “natural” immune system. As a result, in addition to the direct protective effect of natural immunity, antigen‐presenting cells, particularly dendritic cells, are activated to process and present an enormous number of peptide antigens to the T lymphocytes of the adaptive immune system. These, together with the B lymphocytes, then mediate specific immune responses and maintain acquired immunological memory. The aging immune system is less well able to cope with infectious disease than the youthful immune system; this review will briefly consider what is known of the age‐associated alterations in innate immunity, and how these may also impact on adaptive immunity. J. Leukoc. Biol. 64: 703–712; 1998.
- Open Access
- 1 December 1998
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 64 (6) , 733-739
Extrathymic T cell differentiation in vitro from human CD34+ stem cells
Although it is well established that T cells are derived from CD34+ stem cells in vivo, and that T cells can develop in the absence of a functioning thymus, it has not proven possible thus far to generate human T cells in vitro from CD34+ cells in the absence of any thymic influence. We now present a limiting dilution cloning culture system that supports the differentiation of highly purified human CD34+ cells to CD3+ T cells in vitro in the complete absence of any thymic components. The culture system features the use of a serum-free medium supplemented with a cocktail of cytokines including flt-3 ligand, interleukin-3 (IL-3), stem cell factor (SCF), and IL-2. CD4+ T cell clones capable of mitogen-stimulated proliferation and response to IL-2, and expressing a varied TCR-Vβ repertoire were obtained under these conditions. This culture system therefore supports human T lymphopoiesis in the absence of any thymic influence and may prove useful for the evaluation of extrathymic T cell differentiation in vitro. J. Leukoc. Biol. 64: 733–739; 1998.
- 1 December 1998
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 64 (6) , 733-739
Open AccessExtrathymic T cell differentiation in vitro from human CD34+ stem cells
Although it is well established that T cells are derived from CD34+ stem cells in vivo, and that T cells can develop in the absence of a functioning thymus, it has not proven possible thus far to generate human T cells in vitro from CD34+ cells in the absence of any thymic influence. We now present a limiting dilution cloning culture system that supports the differentiation of highly purified human CD34+ cells to CD3+ T cells in vitro in the complete absence of any thymic components. The culture system features the use of a serum-free medium supplemented with a cocktail of cytokines including flt-3 ligand, interleukin-3 (IL-3), stem cell factor (SCF), and IL-2. CD4+ T cell clones capable of mitogen-stimulated proliferation and response to IL-2, and expressing a varied TCR-Vβ repertoire were obtained under these conditions. This culture system therefore supports human T lymphopoiesis in the absence of any thymic influence and may prove useful for the evaluation of extrathymic T cell differentiation in vitro. J. Leukoc. Biol. 64: 733–739; 1998.
- 20 September 1998
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 47 (1) , 32-38
Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells
In a search for potentially tumour-specific MHC-class-II-restricted antigens, the immunogenicity of endogenous peptides that had been eluted from HLA-DR molecules of the human melanoma cell line FM3 (HLA-DRB1*02x, DRB1*0401) was tested in vitro. Two 16-mers representing gp100 positions 44–59, and annexin II positions 208–223 bound well to isolated DRB1*0401 molecules and are discussed here. HLA-DR-matched normal donors' T cells were cultured with peptide-pulsed artificial antigen-presenting cells (CHO cells cotransfected with genes for HLA-DRB1*0401 and CD80 and coexpressing high levels of both human molecules). Specific sensitization was achieved against both peptides, as measured in assays of autocrine proliferation and interleukin-2 secretion. Moreover, responses to native autologous melanoma cells but not to autologous B cells were also observed. In view of the expression of fas by the activated T cells and of fas ligand by the melanoma cells, blockade of potential fas/fas-ligand interactions was undertaken using monoclonal antibodies (mAb). The antagonistic fas-specific mAb M3, but not the fas agonist M33, caused a markedly enhanced T cell response to FM3 cells. These results demonstrate that synthetic peptide antigens are able to sensitize T cells in vitro for effective MHC-class-II-restricted recognition of melanoma cells.
- 20 September 1998
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 47 (1) , 32-38
Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells
In a search for potentially tumour-specific MHC-class-II-restricted antigens, the immunogenicity of endogenous peptides that had been eluted from HLA-DR molecules of the human melanoma cell line FM3 (HLA-DRB1*02x, DRB1*0401) was tested in vitro. Two 16-mers representing gp100 positions 44–59, and annexin II positions 208–223 bound well to isolated DRB1*0401 molecules and are discussed here. HLA-DR-matched normal donors' T cells were cultured with peptide-pulsed artificial antigen-presenting cells (CHO cells cotransfected with genes for HLA-DRB1*0401 and CD80 and coexpressing high levels of both human molecules). Specific sensitization was achieved against both peptides, as measured in assays of autocrine proliferation and interleukin-2 secretion. Moreover, responses to native autologous melanoma cells but not to autologous B cells were also observed. In view of the expression of fas by the activated T cells and of fas ligand by the melanoma cells, blockade of potential fas/fas-ligand interactions was undertaken using monoclonal antibodies (mAb). The antagonistic fas-specific mAb M3, but not the fas agonist M33, caused a markedly enhanced T cell response to FM3 cells. These results demonstrate that synthetic peptide antigens are able to sensitize T cells in vitro for effective MHC-class-II-restricted recognition of melanoma cells.